Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avan Armaghani

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
BMJ Case Reports|April 18, 2015
Hepatoid adenocarcinoma of the colonAvan Armaghani, David Hernandez Gonzalo, Karen Daily
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 21, 2013
Methotrexate nephrotoxicity: Novel treatment, new approachSaima Iqbal, Avan Armaghani, Ravi Aiyer, et al.
Journal of Clinical and Experimental Neuropsychology|June 2, 2009
Visual-spatial disembedding in Parkinson's diseaseGregory P Crucian, Sheyan Armaghani, Avan Armaghani, et al.
Journal of Movement Disorders|November 1, 2014
Dopamine does not appear to affect mental rotation in Parkinson's diseaseGregory P Crucian, Sheyan Armaghani, Avan Armaghani, et al.
Oncology|August 4, 2025
A real-world single-center cohort study on the tolerability of trastuzumab deruxtecan for HER2+ metastatic breast cancerAmeer Basta, Kyle Lien, Weihong Sun, et al.
NPJ Breast Cancer|March 18, 2025
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancerHatem Soliman, Amy Aldrich, Neveen Abdo, et al.
Nature Medicine|March 18, 2023
Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trialHatem Soliman, Deanna Hogue, Hyo Han, et al.
Nature Medicine|February 9, 2023
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trialHatem Soliman, Deanna Hogue, Hyo Han, et al.
JAMA Oncology|December 5, 2024
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical TrialHyo S Han, Amy L Aldrich, Saurabh K Garg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
BMJ Case Reports|April 18, 2015
Hepatoid adenocarcinoma of the colonAvan Armaghani, David Hernandez Gonzalo, Karen Daily
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 21, 2013
Methotrexate nephrotoxicity: Novel treatment, new approachSaima Iqbal, Avan Armaghani, Ravi Aiyer, et al.
Journal of Clinical and Experimental Neuropsychology|June 2, 2009
Visual-spatial disembedding in Parkinson's diseaseGregory P Crucian, Sheyan Armaghani, Avan Armaghani, et al.
Journal of Movement Disorders|November 1, 2014
Dopamine does not appear to affect mental rotation in Parkinson's diseaseGregory P Crucian, Sheyan Armaghani, Avan Armaghani, et al.
Oncology|August 4, 2025
A real-world single-center cohort study on the tolerability of trastuzumab deruxtecan for HER2+ metastatic breast cancerAmeer Basta, Kyle Lien, Weihong Sun, et al.
NPJ Breast Cancer|March 18, 2025
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancerHatem Soliman, Amy Aldrich, Neveen Abdo, et al.
Nature Medicine|March 18, 2023
Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trialHatem Soliman, Deanna Hogue, Hyo Han, et al.
Nature Medicine|February 9, 2023
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trialHatem Soliman, Deanna Hogue, Hyo Han, et al.
JAMA Oncology|December 5, 2024
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical TrialHyo S Han, Amy L Aldrich, Saurabh K Garg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Pageof 1